Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis

BACKGROUND: Targeting the mammalian target of rapamycin by everolimus is a successful approach for renal cell carcinoma (RCC) therapy. The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal gr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Damiano, V, Rosa, R, Formisano, L, Nappi, L, Gelardi, T, Marciano, R, Cozzolino, I, Troncone, G, Agrawal, S, Veneziani, B M, De Placido, S, Bianco, R, Tortora, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668470/
https://ncbi.nlm.nih.gov/pubmed/23571736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.153
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados